|Mr. Donald J. McCaffrey||Co-Founder, Chairman, Pres, CEO & Sec.||676.24k||N/A||N/A|
|Mr. Aaron Bradley Cann CA, CPA, CBV||Chief Financial Officer||322.97k||N/A||N/A|
|Mr. Kenneth Eugene Lebioda BA||Sr. VP of Bus. & Corp. Devel.||304.62k||N/A||N/A|
|Dr. Jan O. Johansson M.D., Ph.D.||Sr. VP of Medical Affairs||315.72k||N/A||N/A|
|Dr. Michael Sweeney M.D.||Sr. VP of Clinical Devel.||628.59k||N/A||56|
Resverlogix Corp., an epigenetics company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibition in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.